Most recent update: Tuesday, May 23, 2017 - 15:27

Bariatric News - Cookies & privacy policy

You are here

Tamoxifen

Tamoxifen protects against obesity-related metabolic disorders

Prevention of high-fat diet-induced glucose intolerance, insulin resistance, and fatty liver (steatosis) by tamoxifen was abrogated in mice with ERα-AF1 deficiency

Tamoxifen, a selective oestrogen receptor modulator, prevents obesity, fatty liver, and insulin resistance in female mice who were fed a high-fat diet and whose ovaries had been removed, according to a study in The American Journal of Pathology. The study was also able to pinpoint which oestrogen receptors underlie these protective effects, opening up possibilities for new therapies to treat these conditions. Tamoxifen is known as the gold standard for endocrine treatment of oestrogen-receptor positive breast cancer.

"For the past two decades, oestrogen receptor α (ERα) has been identified as a key regulator of energy and glucose homeostasis and consequently proposed as a promising target to develop new therapeutic strategies to fight against obesity-related metabolic disorders, such as type 2 diabetes and non-alcoholic fatty liver disease. However, understanding the mechanisms of the metabolic protection conferred by ERα activation has been a crucial challenge," explained Dr Pierre Gourdy, Institut des Maladies Métaboliques et Cardiovasculaires, Université de Toulouse, France.

The paper, ‘{{Selective Activation of Estrogen Receptor α Activation Function-1 Is Sufficient to Prevent Obesity, Steatosis and Insulin Resistance in Mouse," reported that mice whose ovaries had been removed were fed a high-fat diet and treated with either tamoxifen or a placebo for 12 weeks. Investigators found that tamoxifen prevented weight gain, which was attributed to a significant reduction in food intake compared with controls. Tamoxifen-treated mice were less likely to develop glucose intolerance, insulin resistance, as well as deposits of fat in the liver.

Body weight evolution (A) and food intake (B) were recorded weekly. C: Body composition (fat mass) was assessed by magnetic resonance imaging (EchoMRI) after 12 weeks of HFD. D: i.p. glucose tolerance tests were performed after 6 weeks of HFD. E: Insulin resistance was estimated by homeostatic model assessment of insulin resistance (HOMA-IR) score, calculated after 12 weeks of HFD. F: Intrahepatic neutral lipid content and liver histology were assessed at sacrifice. Representative images of hematoxylin and eosin (H&E) and Oil Red O (ORO) staining on liver sections. Insets show higher magnification. Data are expressed as means ± SEM. *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bars: 100 mm (Liver Histology); 50 μm (G, insets). Original magnification, ×40 (insets). VEH-Vehicle alone; TAM-Tamoxifen treated. Credit: The American Journal of Pathology

The researchers knew that ERα exerts its effects through two activation functions known as ERα-AF1 and ERα-AF2, directly involved in the transcriptional regulation of gene expression. Tamoxifen acts as an ERα-AF1 agonist or an ERα-AF2 antagonist according to its tissue/organ targets. To better understand the molecular mechanisms underlying tamoxifen's metabolic effects, the scientists treated mice genetically bred to be deficient either for the entire ER-α (ERα-/-) or just ERα-AF1 (AF1-/-°) with either tamoxifen or placebo and compared the results to wild-type mice (ERα+/+ or AF1+/+) that underwent similar treatment. All the mice were fed a high-fat diet.

Prevention of high-fat diet-induced glucose intolerance, insulin resistance, and fatty liver (steatosis) by tamoxifen was abrogated in mice with ERα-AF1 deficiency. According to Dr. Gourdy, "Altogether, these data indicate that activation of ERα-AF1 by tamoxifen is sufficient to elicit metabolic protective effects in vivo." In addition, the researchers found that selective activation of ERα-AF1 by tamoxifen also regulated most hepatic metabolic genes.

"Altogether, the present study first suggests that the metabolic effects of tamoxifen, as well as other selective modulators of ERα, deserve to be cautiously reconsidered in women, according to their menopausal status. It also opens new perspectives for the treatment of obesity-related complications toward a pharmacologic strategy eliciting selective ERα-AF1 activation," said Gourdy.

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox.